The blood coagulation cascade has recently become a focus of interest in the search for novel treatment targets in neuroinflammatory disorders such as multiple sclerosis (MS). The coagulation protein fibrinogen is known to be deposited in the brain of MS patients following an increased permeability of the blood-brain barrier. Fibrinogen is part of the pathological lesion environment, with pleiotropic roles in the activation of central nervous system (CNS) inflammation, inhibition of tissue repair, and induction of scar formation. 1 These findings make a convincing argument to consider fibrinogen as the key player in the cascade leading to neuronal dysfunction in MS. There is strong evidence, however, that other coagulation proteins are dysregulated in MS-not only in the brain but also in the blood indicating that the role of fibrinogen is overvalued in MS pathophysiology.
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In light of notable recent studies, a number of features argue for a decisive role of coagulation factors in general being the main drivers of MS development and not (only) fibrinogen, as detailed in the following.
The coagulation factor prothrombin (Factor II) is significantly elevated in the blood plasma of individuals suffering from relapsing-remitting MS and secondary progressive MS compared to healthy controls. 2 Changes in prothrombin levels in the plasma allow for a straightforward assessment of disease status, making it possible to employ prothrombin as a helpful marker to differentiate MS patients from healthy individuals. Furthermore, prothrombin levels correlate with disease activity, reflecting phases of relapse. 2 Employing experimental autoimmune encephalomyelitis (EAE), an animal model of MS, could reveal a local increase in the protease thrombin, which is the cleaved form of prothrombin, in the CNS. Importantly, the elevation of thrombin levels precedes the onset of demyelination and neurological signs, 3 suggesting its possible use as an early upstream detector in the serial inflammation process. Interestingly, the inhibition of proinflammatory thrombin signaling through in vivo administration of the anticoagulant hirudin improves the disease course in EAE mice. 4 EAE amelioration resulting from thrombin inhibition is accompanied by a decrease in immune cell proliferation and cytokine secretion, as well as a significant reduction in the number of inflammatory lesions. 4 Since thrombin directly cleaves fibrinogen, it could be argued that the subsequently reduced formation of fibrin is the sole mediator of the observed effects. However, thrombin also activates a proinflammatory signaling cascade through protease-activated receptors (PAR), known to be widely expressed in the CNS. Suppressing this cascade, by inhibiting the generation of thrombin and preventing proinflammatory PAR-1 signaling, is sufficient to improve the course of EAE. 4 Results comparable to those described for prothrombin could as well be shown for the coagulation protein Factor X (FX). FX blood plasma levels in MS patients are significantly increased compared to healthy controls. 2 Moreover, pharmacological inhibition of the enzymatic activity of FX with rivaroxaban leads to an attenuated disease course in EAE, including a decrease in microglial activation and reduced T-cell infiltration. 5 While research has for a long time concentrated on the extrinsic part of the coagulation system, recent investigations have uncovered the important role of the blood coagulation protein Factor XII (FXII). FXII can be activated by plasma kallikrein, plasmin, or negatively charged surfaces in vitro, while in vivo activation is still under debate. 6 Activated FXII (FXIIa) is responsible for initiating the intrinsic coagulation pathway, the kallikrein-kinin system, and complement system. Notably, despite its contribution to in vitro fibrin formation, FXII does not seem to be essential for in vivo hemostasis since a deficiency is not associated with excessive bleeding. 6 Investigating the capacity of FXII as critical trigger of autoimmune inflammation has shown that FXII deficiency leads to an attenuated EAE disease course, accompanied by reduced number of interleukin-17A-producing effector T-helper cells (T H 17). The immune modulatory function of FXII in EAE is mediated by its ability to shift the cytokine profile of dendritic cells in the CNS necessary to induce the differentiation of effector T cells. 7 Pharmacological inhibition of FXII, by recombinant human albumin-tagged infestin-4, also protects from EAE. Strikingly, FXII plasma activity is significantly increased in individuals with relapsing-remitting MS and secondary progressive MS, as compared T Koudriavtseva and M Salvetti to healthy donors, thus indicating a role for this factor in human MS pathogenesis. 7 In particular, besides hemostasis, FXII leads to the activation of the contact system, hereby initiating the release of the proinflammatory peptide hormone bradykinin (BK). Reports on the function of BK in MS and EAE remain contradictory since genetic or pharmacological inhibition of one distinct BK receptor (BK receptor 1 (B1R)) leads to an amelioration of EAE, while another study revealed enhanced inflammation. 8, 9 For MS patients, B1R has been shown to have a detrimental effect, as it is upregulated on T-lymphocytes in patients with either relapsing-remitting or secondary progressive MS during active relapse. 10 Overall, it becomes increasingly clear that the deposition of different coagulation factors in the CNS tissue may trigger exacerbation of neurodegenerative inflammation, thereby limiting regenerative mechanisms crucial for disease recovery. A prominent role besides fibrinogen is especially described for the coagulation proteins prothrombin, FX, and FXII. Since the interplay between inflammatory CNS processes and the coagulation system is eminent, the major challenge for MS research now is to elucidate the exact role of the coagulation cascade and its multiple factors for MS pathophysiology and pick up on the promising leads to identify safe and effective targets for disease intervention. Thus, we should shift our research focus from a detailed examination of only fibrinogen and broaden the picture to include in-depth investigations of other coagulation factors in order to produce more creative and promising therapeutic approaches.
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